Work

555TiP A first-in-human trial of the integrin beta-6-targeted antibody–drug conjugate, SGN-B6A, in patients with advanced solid tumors

Year: 2021

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2021.08.1077

Authors: E. Calvo, A. Hollebecque, A. Dowlati, S.A. Piha-Paul, V. Galvao, J. Lopez, K. Sehgal, B. Bockorny, F. Braiteh, S. Peters, R.E. Sanborn, P. Zhou, N. Nazarenko, A. Patnaik

Institutions: Institut Gustave Roussy, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, The University of Texas MD Anderson Cancer Center, Vall d'Hebron Institute of Oncology, Royal Marsden Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Comprehensive Cancer Centers of Nevada, Centre Hospitalier Universitaire Vaudois, Providence Portland Medical Center, Seagen (United States), South Texas Accelerated Research Therapeutics

Language: English

Topic: Monoclonal and Polyclonal Antibodies Research

Subfield: Radiology, Nuclear Medicine and Imaging

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3204832852

FWCI: 0.122

Cites:

Cited by: 1

Related to: 10